STAT3 Activation as a Predictive Biomarker for Ruxolitinib Response in Head and Neck Cancer.
Zoya QureshyHua LiYan ZengJose M RiveraNing ChengChristopher N PetersonGrace E KimWilliam R RyanPatrick K HaJulie E BaumanSteven J WangSteven R LongDaniel E JohnsonJennifer R GrandisPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Ruxolitinib exhibits antitumor effects in HNSCC preclinical models. Baseline pSTAT3 or total STAT3 levels in the tumor may serve as predictive biomarkers to identify patients most likely to respond to ruxolitinib.